ImmuPharma (LON:IMM) Shares Down 9.9% - Should You Sell?

Key Points

• ImmuPharma plc's share price fell by 9.9%, trading at GBX 10.90 ($0.15) after reaching a low of GBX 10.58 ($0.14).
• The company reported an earnings per share (EPS) of GBX (0.38) for the previous quarter and is expected to post -339.0000022 EPS for the current year.
• ImmuPharma has a market cap of £54.47 million and a notably high negative return on equity of -131.41%.

ImmuPharma plc (LON:IMM - Get Free Report)'s share price fell 9.9% during mid-day trading on Wednesday . The stock traded as low as GBX 10.58 ($0.14) and last traded at GBX 10.90 ($0.15). 14,800,078 shares traded hands during trading, an increase of 72% from the average session volume of 8,597,301 shares. The stock had previously closed at GBX 12.10 ($0.16).

ImmuPharma Trading Down 9.9%

The firm has a market capitalization of £54.47 million, a price-to-earnings ratio of -1,224.72 and a beta of 1.53. The company has a fifty day moving average price of GBX 4.84 and a 200-day moving average price of GBX 3.44.

ImmuPharma (LON:IMM - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. As a group, sell-side analysts predict that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.